Diligence memo · auto-generated · as of July 3, 2026
Virdante Pharmaceuticals, Inc.
Virdante Pharmaceuticals, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Virdante Pharmaceuticals, Inc. operates in Pharmaceuticals, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Virdante Pharmaceuticals, Inc. has raised $30M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $30M on 2008-01-30.
Most recent recorded round closed around 2008-01-30.
Valuation (modeled)modeled
Provath models Virdante Pharmaceuticals, Inc. at approximately $1.0B (range $63M–$3.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.20× the median modeled value of Series B Pharmaceuticals companies in 2007–2009 (9 peers) — value vs value, same stage and era. Within the normal band (120% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 18.4 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 74% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 89% of those peers.
Closest niche peers: Glycomimetics Inc, Avid Radiopharmaceuticals, Inc., Sirion Holdings, Inc., Viamet Pharmaceuticals Inc, Aegerion Pharmaceuticals, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.